Miho Ota1, Takamasa Noda2, Noriko Sato3, Kotaro Hattori4, Toshiya Teraishi4, Hiroaki Hori4, Anna Nagashima4, Keigo Shimoji3, Teruhiko Higuchi5, Hiroshi Kunugi4. 1. Department of Mental Disorder Research, National Institute of Neuroscience, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo, Japan. Electronic address: ota@ncnp.go.jp. 2. Department of Psychiatry, National Institute of Neuroscience, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo, Japan. 3. Department of Radiology, National Institute of Neuroscience, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo, Japan. 4. Department of Mental Disorder Research, National Institute of Neuroscience, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo, Japan. 5. National Center of Neurology and Psychiatry, National Institute of Neuroscience, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan.
Abstract
BACKGROUND: Most previous studies that examined regional cerebral blood flow (rCBF) abnormalities in major depressive disorder (MDD) required the injection of radioisotopes into subjects. Here by using magnetic resonance imaging (MRI) with the pseudo-continuous arterial spin labeling (pCASL) method which does not require radioisotopes, we examined rCBF in patients with MDD in comparison with that in patients with schizophrenia and healthy subjects, taking the regional cerebral gray matter volume into account. METHODS: Subjects were 27 patients with MDD, 42 with schizophrenia and 43 healthy volunteers who underwent 3-T MRI with pCASL. Obtained pCASL imaging data were subject to the voxel-by-voxel statistical analysis. RESULTS: There were significant reductions of rCBF in the right inferior prefrontal cortex and anterior cingulate cortices (ACCs) in the MDD patients compared with the healthy controls. When compared with the schizophrenic patients, the MDD patients showed lower rCBF in the subgenual ACC and higher rCBF in left occipital region. LIMITATION: The abnormalities of rCBF in MDD were known to reverse during symptom remission. Further study with follow-up period would bring the perception about the treatment response. CONCLUSION: The rCBF reduction in the subgenual region may be a specific functional abnormality to MDD patients, which may provide a biological marker for MDD. The MRI with pCASL method is a promising tool to detect rCBF abnormalities controlling for gray matter volume in psychiatric disorders.
BACKGROUND: Most previous studies that examined regional cerebral blood flow (rCBF) abnormalities in major depressive disorder (MDD) required the injection of radioisotopes into subjects. Here by using magnetic resonance imaging (MRI) with the pseudo-continuous arterial spin labeling (pCASL) method which does not require radioisotopes, we examined rCBF in patients with MDD in comparison with that in patients with schizophrenia and healthy subjects, taking the regional cerebral gray matter volume into account. METHODS: Subjects were 27 patients with MDD, 42 with schizophrenia and 43 healthy volunteers who underwent 3-T MRI with pCASL. Obtained pCASL imaging data were subject to the voxel-by-voxel statistical analysis. RESULTS: There were significant reductions of rCBF in the right inferior prefrontal cortex and anterior cingulate cortices (ACCs) in the MDDpatients compared with the healthy controls. When compared with the schizophrenicpatients, the MDDpatients showed lower rCBF in the subgenual ACC and higher rCBF in left occipital region. LIMITATION: The abnormalities of rCBF in MDD were known to reverse during symptom remission. Further study with follow-up period would bring the perception about the treatment response. CONCLUSION: The rCBF reduction in the subgenual region may be a specific functional abnormality to MDDpatients, which may provide a biological marker for MDD. The MRI with pCASL method is a promising tool to detect rCBF abnormalities controlling for gray matter volume in psychiatric disorders.
Authors: Seyed-Parsa Hojjat; Charles Grady Cantrell; Rita Vitorino; Anthony Feinstein; Zahra Shirzadi; Bradley J MacIntosh; David E Crane; Lying Zhang; Sarah A Morrow; Liesly Lee; Paul O'Connor; Timothy J Carroll; Richard I Aviv Journal: Mult Scler Date: 2016-01-11 Impact factor: 6.312
Authors: Nenad Vasic; Nadine D Wolf; Georg Grön; Zrinka Sosic-Vasic; Bernhard J Connemann; Fabio Sambataro; Anna von Strombeck; Dirk Lang; Stefanie Otte; Manuela Dudek; Robert C Wolf Journal: J Psychiatry Neurosci Date: 2015-11 Impact factor: 6.186
Authors: Margarita Abi Zeid Daou; Brian D Boyd; Manus J Donahue; Kimberly Albert; Warren D Taylor Journal: J Affect Disord Date: 2017-03-16 Impact factor: 4.839
Authors: Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz Journal: Neuropsychopharmacology Date: 2017-05-31 Impact factor: 7.853
Authors: Wenjing Wei; Helmet T Karim; Chemin Lin; Akiko Mizuno; Carmen Andreescu; Jordan F Karp; Charles F Reynolds; Howard J Aizenstein Journal: J Clin Psychiatry Date: 2018-10-23 Impact factor: 4.384
Authors: Margarita Abi Zeid Daou; Brian D Boyd; Manus J Donahue; Kimberly Albert; Warren D Taylor Journal: J Psychiatr Res Date: 2017-11-11 Impact factor: 4.791
Authors: Ashley M Darling; Rauchelle E Richey; John D Akins; Erika F H Saunders; R Matthew Brothers; Jody L Greaney Journal: J Affect Disord Date: 2021-08-29 Impact factor: 4.839